{"filing":{"accession_number":"0001628280-26-058512","cik":"0001357874","ticker":"DTIL","company_name":"PRECISION BIOSCIENCES INC","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-24","primary_document":"dtil-20260824.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026058512/dtil-20260824.htm"},"events":[{"id":29039,"run_id":26572,"accession_number":"0001628280-26-058512","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Precision Biosciences announced the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical development milestone marking the transition from preclinical work to human dosing in the company's lead program.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31180,"accession_number":"0001628280-26-058512","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical development milestone for a clinical-stage biotech company—the transition from preclinical work to human dosing in a pivotal trial. While this is an operational/clinical milestone rather than a financial event, M\u0026A activity, or governance matter, it is material to investors assessing the company's pipeline progress and de-risking. The event does not fit neatly into any specific named category but is clearly operational and strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:44.178031+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31181,"accession_number":"0001628280-26-058512","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical milestone for a clinical-stage biotech company—the transition from preclinical development to human dosing in a lead program. While this is an operational/clinical development event rather than a financial, governance, or legal matter, it is material to investors assessing the company's pipeline progress and de-risking of its lead candidate. The event does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:44.178031+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31180,"accession_number":"0001628280-26-058512","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical development milestone for a clinical-stage biotech company—the transition from preclinical work to human dosing in a pivotal trial. While this is an operational/clinical milestone rather than a financial event, M\u0026A activity, or governance matter, it is material to investors assessing the company's pipeline progress and de-risking. The event does not fit neatly into any specific named category but is clearly operational and strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:44.178031+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-08-24"},{"id":31181,"accession_number":"0001628280-26-058512","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosed in the Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. This represents a material clinical milestone for a clinical-stage biotech company—the transition from preclinical development to human dosing in a lead program. While this is an operational/clinical development event rather than a financial, governance, or legal matter, it is material to investors assessing the company's pipeline progress and de-risking of its lead candidate. The event does not fit the specific categories of earnings release, M\u0026A, impairment, or other named types, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T11:01:44.178031+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-08-24"}]}